Integrative analysis of a novel 5 methylated snoRNA genes prognostic signature in patients with glioma.

Abstract

Aim: To explore the prognostic value of methylated snoRNA genes in glioma and construct a prognostic risk signature. Materials & methods: We retrieved clinical information and 450K methylation data from The Cancer Genome Atlas and obtained five methylated snoRNA genes. Then we established a risk signature and verified the effect of SNORA71B on glioma cells with functional assays. Results: A risk signature containing five methylated snoRNA genes was constructed and demonstrated to be an independent predictor of glioma prognosis. Silencing SNORA71B restrained the proliferation, migration and invasion of glioma cells and reduced the expression of mesenchymal and cell cycle marker proteins. Conclusion: This study constructed a methylated snoRNA gene risk signature, which may provide a reference for glioma patients' prognosis assessment.

• Authors: Xiaoyu Yue, Yinfei Zheng, Lianxin Li, Zhihao Yang, Zhigang Chen, Yu Wang, Zhiwei Wang, Deran Zhang, Erbao Bian, Bing Zhao
• Journal: Epigenomics (Epigenomics) Vol. 14 Issue 18 Pg. 1089-1104 (09 2022) ISSN: 1750-192X [Electronic] England
• PMID: 36222052 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cell Cycle Proteins
• RNA, Small Nucleolar

Topics

• Brain Neoplasms (genetics, metabolism)
• Cell Cycle Proteins
• Glioma (genetics, metabolism)
• Humans
• Prognosis
• RNA, Small Nucleolar (genetics)